Literature DB >> 22289055

Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Anthony J Harmar1, Jan Fahrenkrug, Illana Gozes, Marc Laburthe, Victor May, Joseph R Pisegna, David Vaudry, Hubert Vaudry, James A Waschek, Sami I Said.   

Abstract

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are members of a superfamily of structurally related peptide hormones that includes glucagon, glucagon-like peptides, secretin, gastric inhibitory peptide (GIP) and growth hormone-releasing hormone (GHRH). VIP and PACAP exert their actions through three GPCRs - PAC(1) , VPAC(1) and VPAC(2) - belonging to class B (also referred to as class II, or secretin receptor-like GPCRs). This family comprises receptors for all peptides structurally related to VIP and PACAP, and also receptors for parathyroid hormone, corticotropin-releasing factor, calcitonin and related peptides. PAC(1) receptors are selective for PACAP, whereas VPAC(1) and VPAC(2) respond to both VIP and PACAP with high affinity. VIP and PACAP play diverse and important roles in the CNS, with functions in the control of circadian rhythms, learning and memory, anxiety and responses to stress and brain injury. Recent genetic studies also implicate the VPAC(2) receptor in susceptibility to schizophrenia and the PAC(1) receptor in post-traumatic stress disorder. In the periphery, VIP and PACAP play important roles in the control of immunity and inflammation, the control of pancreatic insulin secretion, the release of catecholamines from the adrenal medulla and as co-transmitters in autonomic and sensory neurons. This article, written by members of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) subcommittee on receptors for VIP and PACAP, confirms the existing nomenclature for these receptors and reviews our current understanding of their structure, pharmacology and functions and their likely physiological roles in health and disease. More detailed information has been incorporated into newly revised pages in the IUPHAR database (http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=67).
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22289055      PMCID: PMC3415633          DOI: 10.1111/j.1476-5381.2012.01871.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  177 in total

1.  VIP: the cause of the watery diarrhoea syndrome.

Authors:  I M Modlin; S R Bloom; S Mitchell
Journal:  Adv Exp Med Biol       Date:  1978       Impact factor: 2.622

2.  Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology.

Authors:  Y Wei; S Mojsov
Journal:  J Neuroendocrinol       Date:  1996-11       Impact factor: 3.627

3.  Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung.

Authors:  S Ichikawa; S P Sreedharan; R L Owen; E J Goetzl
Journal:  Am J Physiol       Date:  1995-04

4.  A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.

Authors:  Louise Dickson; Ichiro Aramori; James McCulloch; John Sharkey; Keith Finlayson
Journal:  Neuropharmacology       Date:  2006-08-23       Impact factor: 5.250

5.  Modulation of adrenal catecholamine release by PACAP in vivo.

Authors:  S Lamouche; D Martineau; N Yamaguchi
Journal:  Am J Physiol       Date:  1999-01

6.  Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R).

Authors:  Xenia Beebe; Daria Darczak; Rachel A Davis-Taber; Marie E Uchic; Victoria E Scott; Michael F Jarvis; Andrew O Stewart
Journal:  Bioorg Med Chem Lett       Date:  2008-01-18       Impact factor: 2.823

7.  Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study.

Authors:  H Hashimoto; H Nogi; K Mori; H Ohishi; R Shigemoto; K Yamamoto; T Matsuda; N Mizuno; S Nagata; A Baba
Journal:  J Comp Neurol       Date:  1996-08-05       Impact factor: 3.215

8.  PACAP acts through VIP type 2 receptors in the rat testis.

Authors:  K Krempels; T B Usdin; G Harta; E Mezey
Journal:  Neuropeptides       Date:  1995-12       Impact factor: 3.286

9.  A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells.

Authors:  D A Przywara; X Guo; M L Angelilli; T D Wakade; A R Wakade
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

10.  Distribution of the VPAC2 receptor in peripheral tissues of the mouse.

Authors:  Anthony J Harmar; W John Sheward; Christine F Morrison; Beatrice Waser; Mathias Gugger; Jean Claude Reubi
Journal:  Endocrinology       Date:  2003-11-14       Impact factor: 4.736

View more
  153 in total

1.  Secretin family (Class B) G protein-coupled receptors - from molecular to clinical perspectives.

Authors:  David R Poyner; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  The Role of Neuropeptides in Mouse Models of Colitis.

Authors:  David Padua; John P Vu; Patrizia M Germano; Joseph R Pisegna
Journal:  J Mol Neurosci       Date:  2015-12-08       Impact factor: 3.444

3.  Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice.

Authors:  John P Vu; Mulugeta Million; Muriel Larauche; Leon Luong; Joshua Norris; James A Waschek; Charalabos Pothoulakis; Joseph R Pisegna; Patrizia M Germano
Journal:  J Mol Neurosci       Date:  2014-01-07       Impact factor: 3.444

4.  Evolving pharmacology of orphan GPCRs: IUPHAR Commentary.

Authors:  Anthony P Davenport; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

5.  Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.

Authors:  Venkat Subramaniam; Gin Chuang; Huijing Xia; Brendan Burn; Jessica Bradley; Jerome L Maderdrut; David H Coy; Kurt J Varner
Journal:  Peptides       Date:  2017-07-15       Impact factor: 3.750

Review 6.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 7.  Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Signaling and the Dark Side of Addiction.

Authors:  Olivia W Miles; Victor May; Sayamwong E Hammack
Journal:  J Mol Neurosci       Date:  2018-08-03       Impact factor: 3.444

8.  PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Authors:  Terry W Moody; Lingaku Lee; Tatiana Iordanskaia; Irene Ramos-Alvarez; Paola Moreno; Howard E Boudreau; Thomas L Leto; Robert T Jensen
Journal:  Peptides       Date:  2018-09-28       Impact factor: 3.750

9.  Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.

Authors:  Rebeca Jimeno; Javier Leceta; Carmen Martínez; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Marina Garín; Mario Mellado; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2014-05-08       Impact factor: 3.444

10.  Activation of MEK/ERK Signaling by PACAP in Guinea Pig Cardiac Neurons.

Authors:  Todd A Clason; Beatrice M Girard; Victor May; Rodney L Parsons
Journal:  J Mol Neurosci       Date:  2016-05-18       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.